Mitochondrial dysfunction represents a central pathogenic mechanism in IIMs, tightly interwoven with immune-mediated muscle damage. Targeting both inflammatory and mitochondrial pathways may offer more effective and personalised therapeutic strategies for patients with inflammatory myopathies.
TORRI et al. (Tue,) studied this question.